VANCOUVER, BC, and SAN DIEGO, CA, March 2 /PRNewswire-FirstCall/ - MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Wednesday, March 8th, 2006 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third quarter of fiscal year 2006 ended January 31, 2006 and provide an update on company activities. To participate in the conference call, please dial 416-644-3427 or 1-866-249-1964. The call will be available for replay until March 22, 2006 by calling 416-640-1917 or 1-877- 289-8525 and entering the pass code 21179724 followed by the number sign. The live and archived web cast can be accessed through the company’s website at www.migenix.com for the next 90 days.
About MIGENIX
MIGENIX is committed to advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company’s clinical programs include drug candidates for the treatment of chronic Hepatitis C infections (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I) and the treatment of acne (Phase II). MIGENIX is headquartered in Vancouver, British Columbia, Canada with US operations in San Diego, California. Additional information can be found at www.migenix.com.
CONTACTS Art Ayres Dian Griesel, Ph.D. MIGENIX Inc. Investor Relations Group Tel: (604) 221-9666 Tel: (212) 825-3210 Extension 233 Theproteam@aol.comaayres@migenix.com The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
MIGENIX Inc.
CONTACT: Art Ayres, MIGENIX Inc., Tel: (604) 221-9666, Extension 233,aayres@migenix.com; Dian Griesel, Ph.D., Investor Relations Group, Tel:(212) 825-3210, Theproteam@aol.com; To request a free copy of thisorganization’s annual report, please go to http://www.newswire.ca and clickon Tools for Investors.